The demand for Ioe production of thyroid hormone by the neonate is reflected in a huge surge in TSH in the neonate (Jayasuriya etal, 2018 - see below)

Individuals who may warrant closer monitoring include: Those with a personal or family history of depression , anxiety, or other mood disorders People who have previously experienced mood changes on other weight-loss medications or GLP-1-based therapies Individuals with eating disorders or a complex relationship with food , for whom appetite suppression may have psychological implications (see NICE guideline NG69: Eating disorders: recognition and treatment) [10] Those experiencing significant life stressors alongside starting a new treatment People with poorly controlled type 2 diabetes , where fluctuating blood glucose levels both hypoglycaemia and hyperglycaemia can independently affect mood, concentration, and emotional wellbeing It is also worth acknowledging that obesity itself is associated with higher rates of depression and anxiety, and that the psychological experience of rapid body weight change whether positive or negative can be emotionally complex

Its triple GIP/GLP-1/glucagon agonist mechanism produced the most striking weight-loss numbers ever reported in a Phase 2 trial of an injectable peptide, and its broad TRIUMPH Phase 3 program is poised to expand understanding of how triple receptor modulation affects obesity, diabetes, liver disease, cardiovascular risk, sleep apnea, and musculoskeletal health
doi:10.1016/j.ophtha.2024.03.004 5